INSAN Valuation

Is A277410 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A277410 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A277410 (₩1288) is trading above our estimate of fair value (₩850.86)

Significantly Below Fair Value: A277410 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A277410?

Key metric: As A277410 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A277410. This is calculated by dividing A277410's market cap by their current earnings.
What is A277410's PE Ratio?
PE Ratio	15x
Earnings	₩3.29b
Market Cap	₩49.54b

A277410 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.6x
Enterprise Value/EBITDA	9.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A277410's PE Ratio compare to its peers?

The above table shows the PE ratio for A277410 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	29x
A027050 Coreana CosmeticsLtd	81.7x	n/a	₩75.4b
A353190 Hurum	23.8x	n/a	₩27.6b
A044820 Cosmax BTI	6.7x	n/a	₩80.5b
A270870 Newtree	3.7x	n/a	₩53.7b
A277410 INSAN	15x	n/a	₩49.5b

Price-To-Earnings vs Peers: A277410 is good value based on its Price-To-Earnings Ratio (15x) compared to the peer average (29x).

Price to Earnings Ratio vs Industry

How does A277410's PE Ratio compare vs other companies in the KR Personal Products Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A900120 CXI Healthcare Technology Group	0.7x	n/a	US$15.90m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A277410 is good value based on its Price-To-Earnings Ratio (15x) compared to the KR Personal Products industry average (15.9x).

Price to Earnings Ratio vs Fair Ratio

What is A277410's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A277410 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	15x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A277410's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

NeoPharm

₩185.2b

Engages in the manufacturing and sale of skin care products in South Korea.

A092730

₩11,840.00

-9.0%

5.2%

NOVAREXLtd

₩135.4b

Manufactures, wholesales, and retails health and functional foods in South Korea and internationally.

A194700

₩7,560.00

-0.5%

-32.0%

HuM&C

₩49.3b

Engages in the manufacture and sale of various types of makeup products in South Korea and internationally.

A263920

₩995.00

1.1%

-15.7%